Liquidia (LQDA) Shares Outstanding (2019 - 2026)
Liquidia (LQDA) posted Shares Outstanding (Entity) of $89.1 million for Q2 2026, up 0.9% on a QoQ basis from $88.3 million in Q1 2026, and up 3.77% year-over-year from $85.9 million in Q2 2025.
Analysis
Liquidia (LQDA) Shares Outstanding (2019 - 2026) Analysis & Trends
Liquidia has reported Shares Outstanding (Entity) for 8 years, with the latest figure at $89.1 million in Q2 2026.
- On a quarterly basis, Shares Outstanding (Entity) rose 3.77% year-over-year to $89.1 million in Q2 2026; TTM through Jun 2026 was $89.1 million, a 3.77% increase from a year earlier, with the FY2025 full-year figure at $87.2 million, up 2.98% from the prior year.
- Shares Outstanding (Entity) was $89.1 million for Q2 2026 at Liquidia, up from $88.3 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $89.1 million in Q2 2026, with the low at $53.1 million in Q1 2022.
- Average Shares Outstanding (Entity) over 5 years is $75.2 million, with a median of $76.4 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Entity) grew 0.61% in 2023, then soared 30.27% in 2024.
- Over 5 years, Shares Outstanding (Entity) stood at $64.5 million in 2022, then rose by 6.37% to $68.6 million in 2023, then advanced by 23.39% to $84.7 million in 2024, then climbed by 2.98% to $87.2 million in 2025, then increased by 2.17% to $89.1 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $89.1 million (Q2 2026), $88.3 million (Q1 2026), and $87.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.50 Bn | 622.74 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 440.29 Bn | 433.72 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 364.93 Bn | 357.79 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 266.65 Bn | 258.96 Bn | 11.24 Bn | 1.94 Bn |
| 5 | Pfizer | 158.92 Bn | 147.22 Bn | 10.94 Bn | 5.70 Bn |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | 1.22 Bn |
| 7 | Revolution Medicines | 44.32 Bn | 44.32 Bn | - | 210.89 Mn |
| 8 | Incyte | 25.32 Bn | 20.78 Bn | 1.57 Bn | 200.38 Mn |
| 9 | United Therapeutics | 21.42 Bn | 18.75 Bn | 683.80 Mn | 42.60 Mn |
| 10 | Liquidia | 6.09 Bn | 5.80 Bn | 160.92 Mn | 88.89 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 88.89 Mn |
| Mar 31, 2026 | 88.01 Mn |
| Dec 31, 2025 | 86.06 Mn |
| Sep 30, 2025 | 86.33 Mn |
| Jun 30, 2025 | 85.59 Mn |
| Mar 31, 2025 | 85.17 Mn |
| Dec 31, 2024 | 78.71 Mn |
| Sep 30, 2024 | 78.32 Mn |
| Jun 30, 2024 | 76.44 Mn |
| Mar 31, 2024 | 75.39 Mn |
| Dec 31, 2023 | 64.99 Mn |
| Sep 30, 2023 | 64.86 Mn |
| Jun 30, 2023 | 64.79 Mn |
| Mar 31, 2023 | 64.66 Mn |
| Dec 31, 2022 | 60.96 Mn |
| Sep 30, 2022 | 64.46 Mn |
| Jun 30, 2022 | 62.18 Mn |
| Mar 31, 2022 | 52.47 Mn |
| Dec 31, 2021 | 49.68 Mn |
| Sep 30, 2021 | 52.08 Mn |